RhoA GTPase activation by TLR2 and TLR3 ligands: connecting via Src to NF-kappa B.

Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
The Journal of Immunology (Impact Factor: 5.36). 04/2009; 182(6):3522-9. DOI: 10.4049/jimmunol.0802280
Source: PubMed

ABSTRACT Rho GTPases are essential regulators of signaling networks emanating from many receptors involved in innate or adaptive immunity. The Rho family member RhoA controls cytoskeletal processes as well as the activity of transcription factors such as NF-kappaB, C/EBP, and serum response factor. The multifaceted host cell activation triggered by TLRs in response to soluble and particulate microbial structures includes rapid stimulation of RhoA activity. RhoA acts downstream of TLR2 in HEK-TLR2 and monocytic THP-1 cells, but the signaling pathway connecting TLR2 and RhoA is still unknown. It is also not clear if RhoA activation is dependent on a certain TLR adapter. Using lung epithelial cells, we demonstrate TLR2- and TLR3-triggered recruitment and activation of RhoA at receptor-proximal cellular compartments. RhoA activity was dependent on TLR-mediated stimulation of Src family kinases. Both Src family kinases and RhoA were required for NF-kappaB activation, whereas RhoA was dispensable for type I IFN generation. These results suggest that RhoA plays a role downstream of MyD88-dependent and -independent TLR signaling and acts as a molecular switch downstream of TLR-Src-initiated pathways.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increased endothelial cell (EC) permeability and vascular inflammation along with alveolar epithelial damage are key features of acute lung injury (ALI). Products of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine oxidation (OxPAPC) showed protective effects against inflammatory signaling and vascular EC barrier dysfunction induced by gram negative bacterial wall lipopolysacharide (LPS). We explored more general protective effects of OxPAPC and investigated if delayed post-treatment with OxPAPC boosts the recovery of lung inflammatory injury and EC barrier dysfunction triggered by intratracheal injection of heat-killed gram-positive Staphylococcus aureus (HKSA) bacteria. HKSA-induced pulmonary endothelial cell (EC) permeability, activation of p38 MAP kinase and NFkB inflammatory cascades, secretion of IL-8 and soluble ICAM1, fibronectin deposition and expression of adhesion molecules ICAM1 and VCAM1 by activated EC was significantly attenuated by both, co-treatment and post-treatment with OxPAPC up to 16 hrs after HKSA addition. Remarkably, post-treatment with OxPAPC up to 24 hrs post HKSA challenge dramatically accelerated lung recovery by restoring lung barrier properties monitored by Evans blue extravasation and protein content in bronchoalveolar lavage (BAL) fluid and reducing inflammation reflected by decreased MIP-1, KC, TNFα, IL-13 levels and neutrophil count in BAL samples. These studies demonstrate potent in vivo and in vitro protective effects of post-treatment with anti-inflammatory oxidized phospholipids in the model of ALI caused by HKSA. These results warrant further investigations into potential use of OxPAPC compounds combined with antibiotic therapies as a treatment of sepsis and acute lung injury induced by gram positive bacterial pathogens. Copyright © 2014, American Journal of Physiology - Lung Cellular and Molecular Physiology.
    AJP Lung Cellular and Molecular Physiology 01/2015; 308(6):ajplung.00248.2014. DOI:10.1152/ajplung.00248.2014 · 4.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza infection exacerbates chronic pulmonary diseases including idiopathic pulmonary fibrosis (IPF). A central pathway in the pathogenesis of IPF is epithelial injury leading to activation of transforming growth factor β (TGFβ). The mechanism and functional consequences of influenza-induced activation of epithelial TGFβ are unclear. Influenza stimulates toll like receptor 3 (TLR3), which can increase RhoA activity, a key event prior to activation of TGFβ by the αvβ6-integrin. We hypothesized that influenza would stimulate TLR3 leading to activation of latent TGFβ via αvβ6-integrin in epithelial cells. Using H1152 (IC50 6.1 μM) to inhibit Rho kinase and 6.3G9 to inhibit αvβ6-integrin, we demonstrate their involvement in influenza (A/PR/8/34 H1N1) and poly(I:C) induced TGFβ activation. We confirm the involvement of TLR3 in this process using chloroquine (IC50 11.9 μM) and a dominant negative TLR3 construct (pZERO-hTLR3). Examination of lungs from influenza-infected mice revealed augmented levels of collagen deposition, phosphorylated Smad2/3, αvβ6-integrin and apoptotic cells. Finally, we demonstrate that αvβ6-integrin-mediated TGFβ activity following influenza infection promotes epithelial cell death in vitro and enhanced collagen deposition in vivo and that this response is diminished in Smad3 knockout mice. These data show that H1N1 and poly(I:C) can induce αvβ6-integrin dependent TGFβ activity in epithelial cells via stimulation of TLR3, and suggest a novel mechanism by which influenza infection may promote collagen deposition in fibrotic lung disease.
    Journal of Biological Chemistry 10/2014; 289(51). DOI:10.1074/jbc.M114.582262 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increased vascular smooth muscle cell (VSMC) contraction is an early and critical contributor to the pathogenesis of vascular dysfunction in diabetes; however, knowledge regarding the underlying mechanisms is scarce. Toll-like receptor 2 (TLR2), a well-known component of the innate immunity, is expressed in VSMC and recently has been identified to be systemically activated in diabetes. Whether TLR2 is locally activated in the diabetic blood vessels and have effect on contraction is not known. In the current study, we examined the role of TLR2 in increased vascular contraction in diabetes. Utilizing rat model of type 1 diabetes (induced by streptozotocin (STZ)), we demonstrated that aortas from STZ-diabetic rats exhibit increased expression of TLR2 and its adaptor protein, myeloid differentiation primary response 88 (MyD88), as well as enhanced protein-protein interaction between TLR2 and MyD88, suggesting a TLR2 signaling activation. Blockade of TLR2 in intact aortas using anti-TLR2 antibody attenuated increased vascular contraction in STZ-diabetic rat as assessed by wire myograph. Activation of TLR2 by specific ligand in primary aortic VSMC cultures triggered activation of RhoA which was exacerbated in cells from STZ-diabetic rats than control rats. Activation of RhoA was accompanied by phosphorylation and therefore activation of its downstream targets myosin phosphatase target subunit I and myosin light chain (markers of VSMC contraction). Taken together, these results provide evidence for the role of TLR2 in increased contraction in diabetic blood vessels that involves RhoA signaling. Thus, targeting vascular TLR2 offers a promising drug target to treat vascular dysfunction in diabetes.
    Pflügers Archiv - European Journal of Physiology 01/2015; DOI:10.1007/s00424-015-1688-2 · 3.07 Impact Factor